Pancreatic cancer remains one of the deadliest major cancers. Epidemiologic models estimate that it could become the second leading cause of cancer-related death in the United States by 2030. In 2026, approximately 67,500 U.S. adults are expected to receive a pancreatic cancer diagnosis, while about 52,700 are projected to die from the disease. Across all stages, the five-year survival rate is only 13%. The disease is particularly difficult to treat because it often grows silently until it has invaded nearby blood vessels or spread to distant organs. By the time of diagnosis, fewer than one in five patients are considered candidates for immediate surgery, the only established treatment with potentially curative intent. Most patients therefore require chemotherapy, with radiation increasingly being used to address tumors that remain threatening despite advances in systemic treatment.

The guideline emphasizes that pancreatic cancer treatment must begin with a multidisciplinary assessment. Surgeons, medical oncologists, radiation oncologists, radiologists, pathologists and other specialists must determine whether a tumor can be removed, whether it is close to major blood vessels, how it responds to chemotherapy and whether a patient can safely tolerate intensive treatment. For patients with tumors considered resectable at diagnosis, radiation therapy before surgery, known as preoperative or neoadjuvant radiation, is conditionally recommended. Researchers are still investigating its precise value in this group, but treatment before surgery may sterilize microscopic disease around the tumor, improve local control and increase the likelihood of removing the cancer with clear margins. For patients who do not receive radiation before surgery, postoperative chemoradiation may be considered after multiagent chemotherapy when pathology shows no cancer in the sampled lymph nodes.

The recommendations are stronger for borderline resectable disease, in which a tumor is technically close to or partially involving critical blood vessels and may be difficult to remove completely. In this setting, preoperative radiation therapy or chemoradiation is recommended to improve local control and increase the chance of a margin-negative resection. A margin-negative operation, sometimes called an R0 resection, means that no cancer cells are found at the outer edge of the removed tissue. This distinction is important because residual microscopic disease at the surgical margin can increase the risk of recurrence. Radiation can be delivered together with chemotherapy to damage tumor DNA while chemotherapy sensitizes cancer cells to radiation, although the exact regimen and sequence depend on the patient’s overall condition, tumor anatomy and response to initial treatment.

For patients with locally advanced pancreatic cancer, surgery is often impossible because the tumor has grown around major arteries or veins without yet spreading to distant organs. The updated guideline recommends chemoradiation or radiation therapy after multiagent chemotherapy as definitive treatment in appropriate patients. The goal is not necessarily to eliminate every cancer cell, which may not be realistic in advanced local disease, but to prevent the primary tumor from continuing to invade surrounding structures. Uncontrolled local progression can cause severe pain, intestinal or bile-duct obstruction, bleeding and other complications. Radiation may also help a subset of patients become candidates for surgery if the tumor pulls away from critical vessels or remains stable after treatment. Patients who are medically unable to undergo surgery, or who decline an operation, may likewise receive chemoradiation or radiation following chemotherapy. For individuals at unusually high risk of complications, radiation without initial multiagent chemotherapy may be reasonable.

The guideline also extends radiation’s potential role beyond the initial treatment course. Patients who develop an isolated recurrence near the original surgical site and have never received radiation may be candidates for definitive-intent radiation or chemoradiation. Those who were previously irradiated may be considered for reirradiation, but only after detailed review of the original treatment plan and the doses delivered to nearby organs. Reirradiation is technically demanding because the pancreas lies close to the stomach, small intestine, liver, kidneys and major blood vessels. These tissues have limits on the amount of radiation they can safely receive, and the risk of ulceration, bleeding or perforation must be weighed against the potential benefit of controlling recurrent cancer.

Another emerging area is the treatment of oligometastatic and oligoprogressive disease. Oligometastatic cancer refers to disease that has spread to a limited number of distant sites, while oligoprogressive disease describes a situation in which only a few tumors are growing despite otherwise effective systemic therapy. The guideline conditionally recommends definitive-intent radiation or chemoradiation to selected metastatic lesions and to the original pancreatic tumor when it has not already received definitive local therapy. This approach reflects a broader shift in oncology: as newer drugs, including developing RAS-targeted therapies, help some patients live longer, physicians are increasingly trying to eliminate or suppress individual sites that threaten organs or drive future progression. However, local treatment is not appropriate for every patient and requires careful selection based on tumor biology, the number and location of lesions, previous treatments and expected survival.

Radiation remains especially important when pancreatic cancer causes urgent symptoms. Palliative radiation is recommended for cancer-related bleeding, pain or obstruction, conditions that can rapidly undermine nutrition, mobility and quality of life. In selected patients with painful disease, dose-escalated radiation may provide more durable relief, although higher doses require greater precision and stricter protection of normal tissues. Treatment schedules can range from short courses designed to relieve symptoms quickly to more intensive regimens intended to maintain local control for longer periods. The choice depends on the patient’s performance status, life expectancy, symptoms, anatomy and other treatments. The guideline stresses that the purpose of palliative radiation is not simply to treat an image on a scan, but to reduce suffering and preserve function while avoiding unnecessary treatment burden.

Technological advances are central to the updated recommendations. Intensity-modulated radiation therapy, or IMRT, shapes and modulates radiation beams so that high doses conform more closely to the tumor while limiting exposure to nearby organs. Daily image guidance allows clinicians to verify the tumor’s position immediately before or during treatment. Because the pancreas moves as a person breathes, respiratory-motion assessment and motion-management strategies are also important. Stereotactic body radiation therapy, known as SBRT, delivers highly focused radiation in a small number of treatments, but its safety depends on accurate targeting and adequate separation from vulnerable organs. For dose-escalated SBRT, the guideline recommends adaptive radiation therapy, a process in which the treatment plan can be modified as the patient’s anatomy changes. Tumor shape, stomach filling, bowel position and weight loss can all alter the geometry of treatment, making adaptation a potential safeguard against excessive dose to healthy tissue.

The guideline was developed by a multidisciplinary task force that included radiation, medical and surgical oncologists, a radiation oncology resident, a medical physicist and a patient representative. Its recommendations were based on a systematic review of research published from 2010 through June 2026 and were developed in collaboration with the American Society of Clinical Oncology, the European Society for Radiotherapy and Oncology and the Society of Surgical Oncology. The authors identify major unanswered questions, including how radiation should be combined with rapidly evolving systemic therapies and whether radiation plus RAS inhibitors can improve outcomes. Future research will also need to determine which patients benefit from intensified local treatment and which are more likely to experience harm. For now, ASTRO presents radiation therapy as one component of individualized pancreatic cancer care—neither a universal solution nor a last resort, but a precisely delivered treatment whose value depends on tumor stage, biology, anatomy, previous therapy and the expertise of the team delivering it.

Subject of Research: Radiation therapy for adult patients with pancreatic cancer

Article Title: Radiation Therapy for Pancreatic Cancer: An ASTRO Clinical Practice Guideline

News Publication Date: August 13, 2026

Web References: https://doi.org/10.1016/j.prro.2026.07.002; https://www.practicalradonc.org/article/S1879-8500(26)00217-1/fulltext; https://www.astro.org/

References: American Society for Radiation Oncology (ASTRO) clinical guideline; Practical Radiation Oncology, article publication date August 11, 2026; DOI: 10.1016/j.prro.2026.07.002

Keywords: Pancreatic cancer, radiation therapy, chemoradiation, stereotactic body radiation therapy, SBRT, adaptive radiation therapy, IMRT, cancer treatment, metastatic cancer, clinical guidelines

Pancreatic cancer is notorious for its poor prognosis and limited treatment options, claiming around 52,000 lives annually in the United States alone, according to the American Cancer Society. The inherent challenge in managing this disease lies in its proximity to vital organs like the small intestine. This complication intensifies as high doses of radiation, which are often necessary for effectively targeting the malignancy, can induce severe gastrointestinal toxicity. Traditional method of treating pancreatic cancer has often been obstructed by the serious side effects caused by radiation therapy, making the need for innovative solutions ever more dire.

Dr. Tour’s groundbreaking research on amifostine began nearly twenty years ago, funded by the Defense Advanced Research Projects Agency (DARPA). This initial endeavor focused on finding nanoparticle solutions for radiation poisoning, particularly in the context of nuclear fallout. The concept of repurposing amifostine for the treatment of cancer emerged from these early studies, which investigated the potential of this radioprotective prodrug to shield healthy tissues from the harmful effects of radiation.

Historically, amifostine was developed in the 1970s at Walter Reed Medical Center for intravenous use, and while effective in protecting tissues during radiation therapy, the drug has been stymied by side effects like nausea and hypotension. Consequently, amifostine’s clinical adoption has suffered. Tour’s team shifted their focus towards oral delivery methods that could selectively shield the gastrointestinal tract from radiation damage while minimizing adverse effects. However, they encountered significant challenges, as gastric acids frequently degrade the compound before it can reach the intestines.

Momentum for this research invigorated once again through significant partnerships with esteemed institutions such as MD Anderson Cancer Center. Collaborative efforts led to promising preclinical studies in mouse models, which revealed that mice administered oral amifostine alongside simulated radiation therapy boasted an astounding 100% survival rate after ten days. The efficacy of this treatment was even more pronounced in pancreatic tumor models where the combination nearly tripled survival times. This finding serves as a beacon of hope, suggesting that translating these results to human applications could potentially extend survival durations significantly.

The novel delivery method, shaped by Xerient, a biotech startup founded through partnerships between Rice University and MD Anderson, incorporates either a nasoduodenal tube or a coated oral tablet designed to navigate past the stomach’s acidic environment. This targeted approach aims directly at delivering amifostine to the duodenum, an area particularly susceptible during radiation therapy. By ensuring the drug reaches this critical location, the researchers believe they can administer high-dose radiation safely, while effectively treating pancreatic tumors.

The duodenum’s vulnerability during pancreatic cancer treatment is starkly highlighted by Guy Yachin, co-founder and CEO of Xerient. Their method safeguards this essential area, permitting more aggressive treatments of pancreatic tumors than previously imaginable, without exposing surrounding healthy tissues to the extreme risks posed by high-dose radiation. By utilizing precise delivery strategies, Xerient’s innovation enables robust doses of radiation designed to enhance survival rates for individuals with unresectable pancreatic tumors.

In light of these developments, the research team is preparing to transition to clinical phases of their work, specifically targeting phase 1 and 2 clinical trials. These trials will ascertain the safety and effectiveness of their nasoduodenal tube delivery system while ensuring precise drug administration directly to the duodenum. Yachin noted the variety of benefits this nasogastric delivery system could provide, including optimized drug activation and the need for reduced idle time when using radiation machinery.

Furthermore, the promise of amifostine extends beyond treating pancreatic cancer. Given the drug’s radiation-protective qualities, it holds potential applications in managing other abdominal and pelvic cancers, such as hepatobiliary tumors and metastatic diseases located in the abdomen. The versatility of this innovation is monumental, highlighting the capacity of repurposed drugs to address various oncological and non-oncological challenges.

Tour’s team envisions a far-reaching future for their innovation, suggesting it could not only advance cancer treatment significantly but also provide protection for astronauts exposed to solar radiation, as well as stand as a crucial emergency measure during nuclear disasters. The research fundamentally aims to alleviate one of the most pressing clinical needs by repurposing a well-known drug to extend treatment options and safeguard lives in scenarios where traditional methods fall short.

The collective efforts of researchers at Rice University and their partner institutions exemplify the immense potential that exists at the intersection of innovative science and clinical application. The convergence of historical research, novel drug delivery systems, and collaborative efforts signals a promising future in the fight against pancreatic cancer, heralding a new era where more patients may gain access to effective treatments that mitigate suffering and enhance life expectancy.

The road ahead is filled with challenges that still lie within the realm of regulatory hurdles and the meticulous process of clinical trials. However, the initial promise shown by the research and its transformative implications for cancer therapy represent a significant shift toward more effective, safer treatments that could one day change the narrative for patients diagnosed with pancreatic cancer.

The anticipation surrounding the forthcoming clinical trials and their results remains palpable. If successful, these trials could represent a landmark shift in treatment paradigms, elevating the standards of care for patients battling an immensely challenging diagnosis. The broader medical community and patients alike look forward to witnessing the impact of science and innovation in combating one of the most formidable adversaries in oncology.

Subject of Research: Targeted delivery of amifostine for pancreatic cancer treatment through nasal methods
Article Title: Revolutionary Approach to Pancreatic Cancer Therapy via Targeted Nasal Delivery
News Publication Date: [TBD]
Web References: [TBD]
References: [TBD]
Image Credits: Brandon Martin/Rice University
Keywords: Pancreatic cancer, amifostine, radiation therapy, drug delivery, clinical trials, cancer treatment, gastrointestinal protection, biotechnological innovation, chemotherapy, cancer research.